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KidneyTransplantation

Antithrombin Perfluorocarbon Nanoparticles
Improve Renal Allograft Function in a Murine
Deceased Criteria Donor Model
Chandu Vemuri, MD,1,2 Gundumi A. Upadhya, MD,1 Batool Arif, MD,1 Jianluo Jia, MD,1 Yiing Lin, MD, PhD,1
Joseph P. Gaut, MD, PhD,3,4 Jawad Fazal, MD,5 Hua Pan, MD,5 Samuel A. Wickline, MD,3,5
and William C. Chapman, MD1

Background. Over 100000 patients await renal transplantation and 4000 die per year. Compounding this mismatch between
supply and demand is delayed graft function which contributes to short-term and long-term graft failures. Previously, we reported
that thrombin-targeted perfluorocarbon nanoparticles (PFC-NP) protect kidneys from ischemic renal injury after transient arterial
occlusion. Here we hypothesize that perfusion of renal allografts with PFC-NP similarly can protect graft function after an ischemic
interval. Methods. After 60 minutes of warm ischemia, male Lewis rats underwent left renal explantation followed by renal perfusion with 5 mL of standard perfusate alone (N = 3) or with 0.3 mL of untargeted PFC-NP (N = 5) or 0.3 mL thrombin-targeted of
PFC NP functionalized with phenylalanine-proline-arginine-chloromethylketone (PPACK) (PFC-PPACK), an irreversible thrombin
inhibitor (N = 5). Kidneys underwent 6 hours of cold storage, followed by transplantation into recipients and native nephrectomy.
Animals were euthanized at 24 hours for tissue collection or at 48 hours for blood and renal tissue collection. A survival experiment
was performed using the same protocol with saline control (N = 3), PFC-NP (N = 3) or PFC-PPACK (N = 6). Results. Serum creatinine was improved for the PFC-PPACK groups as compared with control groups (P < 0.04). Kaplan-Meier survival curves also
indicated increased longevity (P < 0.05). Blinded histologic scoring revealed markedly attenuated renal damage in the PFC-PPACK
group compared to untreated animals (2.75 ± 1.60 versus 0.83 ± 3.89; P = 0.0001) and greater preservation of renal vasculature.
Conclusions. These results validate an NP-based approach to improve renal graft function as antithrombin NPs improved allograft function, decreased renal damage, protected vasculature, and improved longevity.

(Transplantation Direct 2018;4: e384; doi: 10.1097/TXD.0000000000000817. Published online 21 August, 2018.)

I

n the United States alone, over 100000 patients are listed
for renal transplantation for end-stage renal disease with
an expected median wait time of 3.6 years. The incidence of
renal failure requiring transplant is expected to increase while
the number of available organs remains limited. This mismatch of supply and demand results in more than 4000
deaths per year. (www.kidney.org/news/newsroom/
factsheets/Organ-Donation-and-Transplantation-Stats).
Received 11 October 2017. Revision requested 19 June 2018.

To address this critical shortage, donor organs are sought
from living donors and deceased donors with extended
criteria in specific circumstances. As critical as it is to receive
a renal transplant, it is equally important that the transplant
performs well in the recipient. One aspect needing improvement
is renal preservation after organ recovery. Currently, after explantation, organs are perfused with University of Wisconsin's
(UW) preservation solution and stored at 4°C. Although cold
perfusion is intended to decrease cellular metabolism and
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reduce cellular injury, significant ischemia reperfusion injury
(IRI) may occur. Ischemia-reperfusion injury causes delayed
graft function, long-term graft dysfunction, and poor overall
patient outcomes. Thus, a clear clinical need exists for better
renal preservation postexplantation.1-4
Thrombin is one agent that plays a role in IRI. Thrombin
adversely affects renal transplant outcomes through activation
of the coagulation cascade and subsequent microvascular
thrombosis. Furthermore, thrombin can activate proteaseactivated receptors, which are abundant in the kidney,
resulting in a proinflammatory state.5 Systemic thrombin inhibition has been shown to be effective in improving renal
acute and chronic allograft function in animal models.6
However, systemic thrombin inhibition is accompanied by
bleeding risk that limits its use in the setting of major surgery, such as renal transplantation.
Here we propose nanoparticle (NP)-based antithrombin
therapy as a safer strategy for renal preservation when incorporated into a preservation solution. We have developed a
perfluorocarbon NP (PFC-NP) platform that inhibits thrombin locally without causing a bleeding diathesis, and which
forestalls thrombin signaling and microvascular thrombosis
in atherosclerosis and renal ischemic injury.7-10 To this end,
PFC-NP were modified to incorporate a well-known antithrombin moiety, proline-phenylalanine-arginine-chloromethylketone
(PPACK), which has been shown to limit acute kidney injury
following transient warm ischemia in murine models with no
systemic toxicity or bleeding risk.9,10 Accordingly, in this work,
we sought to determine if perfusion of explanted kidneys
with antithrombin NPs might improve graft function in a rodent model of deceased criteria donor renal transplantation.
MATERIALS AND METHODS
Animal Protocol

Animal experiments were approved by the Washington
University Animal Studies Committee. Male Lewis rats
(275Y300 g; Charles River Laboratories, Wilmington, MA)
were housed in controlled environments. The experimental
procedural time line is shown in Figure 1. The donor animal
was anesthetized with 2% isoflurane, and the left kidney
was mobilized. The aorta was clamped proximal and distal
to the renal arteries to create 60 minutes of warm ischemia,
and kidneys were explanted and manually perfused through
a 25-gauge needle with 5 mL of UW alone (N = 3) or along
with 0.3-mL PFC-NP (N = 5) or 0.3-mL PFC-PPACK (N = 5).

FIGURE 1. Timeline of experimental procedures.
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The infrarenal inferior vena cava was transected distal to
the renal veins. The left kidney was then placed in UW to create 6 hours of cold ischemia. A syngeneic recipient was then
anesthetized, and a left nephrectomy was performed. The
transplant was performed first with the arterial anastomosis
using the end-in-end sleeve technique in which the recipient
renal artery was telescoped into the donor renal artery and
then fixed in place with sutures.11 The donor inferior vena
cava was anastomosed end-to-end using a cuff technique.
The donor renal vein was passed through and then everted
through a cuff. The donor cuffed vein was then telescoped
through the recipient renal vein and then fixed into place
with sutures. The ureter was anastomosed to the bladder,
and a right nephrectomy was performed.12 For short-term
assessment, rats were euthanized at 48 hours and blood
and renal tissue collected. The same protocol was followed
to obtain additional renal tissue for histologic analysis: saline
alone (N = 3) or PFC-PPACK (N = 3), euthanized at 24 hours.
For survival assessment, the same protocol was followed (saline alone [N = 3], PFC-NP [N = 3], PFC-PPACK [N = 6])
with postoperative observation until death.
Blood Sample and Tissue Processing

Blood was processed at the Core Research Animal Diagnostic Laboratory, Washington University School of Medicine. The samples were analyzed using the LIASYS 330
(Charleston, SC) clinical chemistry system and blood urea nitrogen (BUN) and creatinine reported in mg/dL.
The transplanted kidney was excised at the time of euthanasia, formalin-fixed, and paraffin embedded and then stained
with hematoxylin and eosin (H&E). All microscopic evaluations were performed blinded by a single pathologist (J.P.G.)
using an Olympus BX51 (Melville, NY) microscope outfitted
with an Olympus DP71 (Melville, NY) digital camera. Five
representative digital images of the renal cortex were sampled
randomly from 1 representative H&E-stained section and
photographed at 400 magnification. All tubules in each image were counted and scored as necrotic (coagulative-type necrosis) or viable. The ratio of necrotic to total tubules was used
as a quantitative assessment of acute tubular necrosis. Vascular injury was scored in a similar fashion, and injury was established by necrosis of the vascular wall.
To quantify overall renal vascular prevalence, rats received
an intravenous injection of 500 μL of DyLight 594 labeled
Lycopersicon Esculentum (tomato) lectin (Cat: DL-1177;
Vector Labs, Burlingame, CA). Excised kidneys were embedded
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in O.C.T. (Cat: 102094-106; VWR, Radnor, PA) and sectioned for fluorescence microscopic imaging using an Axio
Scan.Z1 (Zeiss, Thornwood, NY). All images were acquired
at the same power settings, exposure times, and digitization
parameters. Total lectin fluorescence intensity of whole kidney sections served as a surrogate for vascular preservation
as analyzed with ImageJ (NIH, Bethesda, MD).
NP Formulation

Perfluorocarbon NP (∼250 nm) were formulated with either
perfluorooctylbromide (PFOB) or perfluoro-15-crown-5-ether
(CE) as previously described.9 The PFOB emulsion was composed of 20% (vol/vol) of PFOB (Exfluor Research), 2.0%
(wt/vol) of a surfactant commixture, and 1.7% (w/vol) glycerin, with water comprising the balance. The CE emulsion
was composed of 40% (vol/vol) of CE (Exfluor Research),
2.0% (wt/vol) of a surfactant commixture, and 1.7% (wt/vol)
glycerin, with water comprising the balance. Phenylalanineproline-arginine-chloromethylketone was conjugated to the
PFOB NP using a previously reported method that loaded
∼13650 PPACK moieties per particle.9
Statistical Analysis

All statistical analyses were performed with SAS software
(SAS Institute). Quantitative data (BUN, creatinine, vascular
preservation) are reported as mean ± SEM. Analysis of variance (ANOVA) and unpaired Student t test was used to determine statistical differences. The log-rank test was used to
analyze survival for PFC-NP and PFC-PPACK groups.

RESULTS
Renal Functional Data

The standard perfusate group exhibited a mean BUN (mg/dL)
of 225.33 ± 11.62, the PFC-NP a mean of 245.33 ± 1.33, and
the PFC-PPACK group a mean of 103.00 ± 17.04 (Figure 2).
For creatinine (mg/dL), the standard perfusate group exhibited a mean of 6.25 ± 0.70, the PFC-NP a mean of 5.16 ±
0.06 and the PFC-PPACK group a mean of 1.89 ± 0.50
(Figure 3). By ANOVA, a statistically significant difference
was observed between treatment and control groups for both
BUN and creatinine (P < 0.05). No bleeding complications
were observed in any group.

FIGURE 2. Improved renal allograft function in treatment (n = 5) versus control groups at 48 hours (standard, n = 3; PFC-NP, n = 5). The
y-axis represents serum BUN level and the x-axis is treatment group.
*Statistically significant difference between PFC-PPACK and control
groups by ANOVA (P < 0.01).

FIGURE 3. Improved renal allograft function in treatment (n = 5) versus control groups at 48 hours (standard, n = 3; PFC-NP, n = 5). The
y-axis represents serum creatinine and the x-axis is treatment group.
*Statistically significant difference between PFC-PPACK and control
groups by ANOVA (P < 0.01).

Renal Parenchymal and Vascular Injury

The ratio of necrotic to intact tubules was used as a metric
of renal injury. The percentage (%) of parenchymal tubular
necrosis in the PFC-NP group was 71.9 ± 2.8 versus 12.19 ±
1.24 in the PFC-PPACK group (P < 0.05; Student t test).
No arteries exhibited intimal mucoid edema, thrombi, or
fragmented red blood cells within the vascular walls. The ratio of injured vessels to total number of vessels (%) was used
to quantify vascular injury. Vascular injury in the PFC-NP
was 50.14 ± 13.56 versus 28.4 ± 12.04 in the PFC-PPACK
group (P = 0.282; Student t test) (Figures 4-6). Analysis
of renal vasculature preservation with lectin staining (arbitrary units) revealed significantly greater signal in the PFCPPACK group compared with saline control 3672.92 ±
274.74 versus 2098.39 ± 426.38 (P = 0.006; Student t test)
(Figures 7-8).
Survival Data

Given the severe nature of the renal injury, all subjects expectedly died from renal failure, although longevity was
lengthened in the treated group. The mean survival in the
group treated with PFC-PPACK was 6 days versus 4 days
for the control groups (PFC-NP and saline) (Figure 9), which

FIGURE 4. Parenchymal and vascular injury after treatment (N = 5)
versus PFC-NP control (N = 3 per group). The y-axis represents percent injury and the x-axis is treatment group grouped by metric after
48 hours. There was a statistically significant difference in parenchymal injury (P < 0.05) and no significant difference in vascular injury
(P = 0.282).
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FIGURE 5. A, Representative image of a saline treated kidney demonstrating marked coagulative type acute tubular necrosis (arrows) (H&E,
400). B, Representative image of a PFC-PPACK treated kidney with essentially no observable tubular necrosis (arrows) (H&E, 100).

was statistically significant by log-rank survival analysis
(P = 0.005).
DISCUSSION
The incidence of end-stage renal disease requiring transplant continues to rise yet there is a critical shortage of available organs. Compounding this shortage is the issue of acute
and delayed graft function that often ensues from inadequate
protection of explanted organs. Furthermore, patients with
poor graft function suffer worse outcomes with respect to
function of the transplanted organ and overall survival. Improvements in surgical technique and immunosuppressive
therapies have improved outcomes, but transplanted organs
can suffer significant IRI after the pretransplant period of
warm and/or cold ischemia.1-3 Unfortunately, specific therapies that address IRI in renal transplant during renal preservation are lacking.
After transient ischemia, reperfusion results in immediate
renal injury due to a combination of microvascular thrombosis and inflammation which then synergistically compound renal injury during the extension phase.13 Thrombin is involved
in IRI in both microvascular thrombosis and activation of

proinflammatory pathways through vascular protease activated receptors.5 Other groups have reported improved acute
and chronic graft function for renal allografts in pigs systemically treated with the intravenous thrombin inhibitor
Megalatran.6 However, this therapy has not been adopted
for routine patient care as recent reports have noted a surprising risk of glomerular hemorrhage and tubular obstruction with the direct thrombin inhibitor dabigtran.14
Accordingly, an opportunity exists to develop more selective and targeted therapeutics to limit IRI in renal grafts.
We have reported previously the development of a safe and
effective PFC-NP platform for cardiovascular imaging and
therapeutics.7,8 Perfluorocarbon NP consist of a liquid PFC
core encapsulated by an outer phospholipid shell in a diameter range of 160 to 300 nm. These particles can be functionalized by surface modifications through covalent incorporation
of targeting molecules situated in the lipid shell. Here we used
PPACK to serve an irreversible inhibitor of thrombin on
PFC-NP. Native PPACK is plagued by a short half-life when
used systemically as a single agent, rendering it clinically ineffective. However, incorporation of PPACK into an NP allows
targeted delivery of substantial quantities of the antithrombin agent per each PFC-NP to the sites of active vascular

FIGURE 6. Representative images highlighting renal vascular injury in the PFC-NP (A-C) group compared with PFC-NP PPACK (D-F).
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FIGURE 7. Representative images illustrating preservation of renal vasculature after treatment. Greater lectin staining is apparent in kidneys
treated with PFC-NP PPACK (A-C) as compared to saline (D-F) treatment.

thrombosis while limiting bleeding risk due to rapid diminution of systemic anticoagulant effect via hepatic sequestration
of nontargeted particles.8,9 We have demonstrated previously
the ability of PFC-NP PPACK to decrease the time to occlusion
in a murine model of arterial injury while only transiently affecting systemic coagulation parameters for less than 60 minutes as
the PFC-NP are cleared.9 Moreover, we have shown that
PFC-NP PPACK can attenuate renal injury after transient
warm ischemia in a murine model of renal ischemia.10
We hypothesized that by perfusing explanted organs with
PFC-NP PPACK, we could preserve acute graft function, prevent renal parenchymal and vascular injury, and improve animal survival. Although PPACK itself is not entirely specific
for thrombin, it is clearly useful in this ex vivo application.
To demonstrate the flexibility of this approach, we have reported the substitution of more selective inhibitors of thrombin
such as bivalirudin.9 Regardless of the specific clot inhibiting
moiety incorporated, the pharmacokinetics of the PFC-NP
depends only on the particle itself and systemic clotting parameters and bleeding times normalize after 30-60 min when

administered intravenously.9 Of note, we choose to treat the
explanted donor kidneys before cold perfusion to prevent local activation of thrombin during cold perfusion. Using this
approach, there were no apparent bleeding complications
in the recipient animals.
The present data demonstrate improvements in acute graft
function according to BUN and creatinine measures. Blinded
histologic analysis revealed significantly decreased renal tubular necrosis but a nonsignificant trend toward reduced vascular injury in the treatment groups as compared to controls.
Additionally, despite the severe injury imposed by this murine
deceased criteria donor renal transplant model, the PFC-NP
PPACK treatment extended survival from 4 to 6 days as compared with standard therapy. To begin to explore the basis
for improved renal allograft function, we performed vascular
staining with lectin and observed significantly greater vascular abundance in the PFC-NP PPACK treated animals. We
suggest that the preservation of renal vasculature may represent in part a physiological basis for improved allograft
function in the PFC-NP PPACK groups by limiting vascular

FIGURE 8. Vascular preservation according to lectin staining after treatment in the PPACK treated (N = 3) versus saline control treated (N = 3)
group (P < 0.05). The y-axis represents lectin staining fluorescence intensity (arbitrary units (a.u.)) and the x-axis is treatment group at 24 hours.
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versus Factor Xa, it is highly likely that thrombin inhibition
is responsible for the functional salvage.8,9 Lastly, the animal
model used may not be entirely representative of the human
transplant situation and therefore results could differ in translation to patients.
In conclusion, renal graft IRI continues to hinder acute and
long-term kidney function after renal transplantation. There
is a clear clinical need for more selective prophylactic therapeutics to enhance renal preservation. This work demonstrates the potential beneficial effects of PFC-NP PPACK on
both functional and structural measures of renal graft injury
and suggests improved acute survival. Future work will be
aimed at understanding the mechanistic basis of these results
and optimizing this therapy to improve outcomes in human
transplantation of kidneys and other organs.

FIGURE 9. Survival times after treatment. Male Lewis Rats underwent left renal explantation followed by perfusion of standard solution
with normal saline control (n = 3), PFC-NP (n = 3) or PFC-PPACK
(n = 6). Kidneys then underwent 60 minutes of warm ischemia and
6 hours of cold incubation, followed by transplantation into recipients and native nephrectomy. The y-axis represents percent survival
and the x-axis represents days posttransplant. The treatment group
exhibited extended survival as compared to the control group
(P = 0.005 by log-rank analysis).

pruning after IRI. We speculate that the lack of statistical
significance for vessel injury metrics can be attributed to
the subsequent pruning and dissolution of irreversibly damaged vessels and partial to near complete recovery of those reversibly damaged. It should be noted that lectin staining of
endothelium is only 1 method for examining vascular integrity
but it is objective when applied to the entire organ as compared
with selections of regions of interest for vascular counting, and
it poses an interesting subject for future investigation.
This work is subject to several limitations. Importantly,
this is a pilot trial of PFC-NP PPACK in a limited set of experimental subjects addressing acute parameters. Ultimately,
additional studies with larger numbers will be required to
confirm long-term benefits. However, it is known that acute
graft function after implantation correlates directly with
long-term graft function.1,2 The particular dosing regimen
with respect to drug volume, amount, and timing of administration were extrapolated from other work and can be refined
experimentally. Additionally, as the organs were perfused with
NPs before cold storage and transplantation, there was no actual verification of local inhibition of thrombin by PFC-NP
PPACK. However, as there is only a single active pharmacological ingredient that yields a known antithrombotic function
that is several orders of magnitude more potent for thrombin
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